NYSE:NVS - Novartis Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $88.13
  • Forecasted Upside: 5.25 %
  • Number of Analysts: 12
  • Breakdown:
  • 2 Sell Ratings
  • 8 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$83.73
▼ -0.55 (-0.65%)

This chart shows the closing price for NVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novartis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVS

Analyst Price Target is $88.13
▲ +5.25% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $88.13, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 5.25% upside from the last price of $83.73.

This chart shows the closing price for NVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 12 contributing investment analysts is to hold stock in Novartis. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 2 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 3 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 3 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 3 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 3 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 2 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 2 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 2 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/29/2022Deutsche Bank AktiengesellschaftLower Price TargetCHF 80 ➝ CHF 75Low
6/3/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
5/9/2022Wolfe ResearchDowngradeOutperform ➝ Market PerformMedium
5/6/2022Morgan StanleyBoost Price TargetCHF 90 ➝ CHF 94Low
4/28/2022Credit Suisse GroupBoost Price TargetCHF 85 ➝ CHF 88Medium
4/27/2022UBS GroupBoost Price TargetNeutral ➝ NeutralCHF 85 ➝ CHF 88Medium
4/14/2022BarclaysBoost Price TargetCHF 80 ➝ CHF 85Low
4/8/2022UBS GroupBoost Price TargetCHF 84 ➝ CHF 85Low
2/28/2022Stifel NicolausInitiated CoverageHoldLow
2/3/2022Societe GeneraleLower Price TargetCHF 107 ➝ CHF 105Low
1/10/2022CitigroupInitiated CoverageBuyMedium
12/14/2021Redburn PartnersDowngradeBuy ➝ NeutralMedium
12/6/2021Exane BNP ParibasDowngradeOutperform ➝ NeutralCHF 85Low
12/6/2021BNP ParibasDowngradeOutperform ➝ NeutralMedium
12/3/2021Bryan, Garnier & CoReiterated RatingBuy ➝ Neutral$115.00 ➝ $85.00Low
11/5/2021UBS GroupDowngradeBuy ➝ NeutralLow
10/27/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
10/12/2021Berenberg BankReiterated RatingBuyLow
10/8/2021UBS GroupReiterated RatingBuyLow
9/20/2021Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellMedium
7/28/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
7/22/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
5/11/2021Morgan StanleyReiterated RatingOverweightLow
4/28/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
4/28/2021Oddo BhfUpgradeNeutral ➝ OutperformLow
4/19/2021UBS GroupReiterated RatingBuyLow
3/23/2021Societe GeneraleReiterated RatingBuyLow
3/22/2021Sanford C. BernsteinInitiated CoverageMarket PerformMedium
3/16/2021ArgusReiterated RatingBuy ➝ HoldLow
3/10/2021ArgusDowngradeBuy ➝ HoldLow
2/2/2021Morgan StanleyReiterated RatingOverweightLow
2/1/2021CowenDowngradeOutperform ➝ Market Perform$110.00 ➝ $105.00Low
1/22/2021BarclaysReiterated RatingUnderweightMedium
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
1/8/2021Morgan StanleyReiterated RatingOverweightLow
12/3/2020ArgusBoost Price Target$100.00 ➝ $112.00Low
11/25/2020UBS GroupReiterated RatingBuyLow
11/10/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
9/29/2020Berenberg BankInitiated CoverageBuyMedium
9/23/2020Oddo BhfDowngradeBuy ➝ NeutralLow
9/10/2020UBS GroupUpgradeNeutral ➝ BuyLow
9/1/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
8/12/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
7/28/2020Morgan StanleyReiterated RatingEqual WeightLow
6/15/2020CitigroupUpgradeNeutral ➝ BuyLow
5/11/2020UBS GroupReiterated RatingNeutralMedium
4/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
4/29/2020BarclaysReiterated RatingUnderweightLow
4/23/2020Morgan StanleyReiterated RatingEqual WeightLow
4/3/2020The Goldman Sachs GroupReiterated RatingBuy$116.00High
3/10/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
2/25/2020GuggenheimDowngradeBuy ➝ NeutralHigh
2/17/2020CitigroupDowngradeBuy ➝ NeutralLow
10/25/2019CowenReiterated RatingBuy$100.00Low
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
7/23/2019ArgusBoost Price TargetBuy$105.00Low
7/23/2019Kepler Capital MarketsDowngradeBuy ➝ HoldLow
7/5/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
4/25/2019Liberum CapitalUpgradeHold ➝ BuyLow
4/24/2019GuggenheimUpgradeNeutral ➝ Buy$79.16Medium
4/10/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$82.50 ➝ $82.52Low
1/29/2019JPMorgan Chase & Co.Reiterated RatingSellLow
1/16/2019JPMorgan Chase & Co.Reiterated RatingSellLow
1/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
12/20/2018Credit Suisse GroupDowngradeSellLow
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy$105.00Low
12/7/2018BarclaysDowngradeEqual Weight ➝ SellLow
12/2/2018CowenUpgradeMarket Perform ➝ Outperform$88.03Low
11/28/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
11/26/2018CowenUpgradeMarket Perform ➝ Outperform$100.00Low
11/16/2018The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-BuyLow
11/6/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/23/2018Wolfe ResearchInitiated CoverageOutperformMedium
10/18/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
10/10/2018The Goldman Sachs GroupReiterated RatingNeutralMedium
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
9/11/2018BNP ParibasUpgradeUnderperform ➝ NeutralLow
9/11/2018Exane BNP ParibasUpgradeUnderperform ➝ NeutralLow
9/11/2018CitigroupUpgradeNeutral ➝ BuyLow
9/10/2018Bank of AmericaUpgradeUnderperform ➝ Buy$74.71Low
7/19/2018BarclaysUpgradeUnderweight ➝ Equal WeightLow
7/19/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/19/2018DZ BankReiterated RatingBuyLow
5/29/2018HSBCDowngradeBuy ➝ HoldLow
5/25/2018Credit Suisse GroupUpgradeUnderperform ➝ NeutralLow
5/17/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/20/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
4/10/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
4/9/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/18/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/15/2018UBS GroupReiterated RatingNeutralLow
1/2/2018Nord/LBReiterated RatingNeutralMedium
12/27/2017Nord/LBReiterated RatingNeutralLow
12/6/2017Bank of AmericaDowngradeNeutral ➝ UnderperformLow
10/31/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
10/25/2017BarclaysDowngradeEqual Weight ➝ UnderweightN/A
10/24/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
10/23/2017SVB LeerinkBoost Price TargetMarket Perform$89.00 ➝ $91.00N/A
10/10/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
9/26/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/5/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/29/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/9/2017CowenSet Price TargetHold$90.00Medium
7/26/2017Morgan StanleyUpgradeUnderweight ➝ OverweightLow
7/18/2017CowenReiterated RatingHoldLow
7/17/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/11/2017CowenSet Price TargetHold$77.00Low
7/10/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
(Data available from 7/7/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 22 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
12/8/2021
  • 6 very positive mentions
  • 31 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
1/7/2022
  • 6 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/6/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/8/2022
  • 8 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2022
  • 5 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
5/7/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
6/6/2022
  • 8 very positive mentions
  • 19 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
7/6/2022

Current Sentiment

  • 8 very positive mentions
  • 19 positive mentions
  • 9 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Novartis logo
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $83.73
Low: $83.19
High: $84.02

50 Day Range

MA: $86.31
Low: $80.52
High: $91.93

52 Week Range

Now: $83.73
Low: $79.09
High: $95.17

Volume

1,791,334 shs

Average Volume

1,892,106 shs

Market Capitalization

$185.26 billion

P/E Ratio

7.80

Dividend Yield

2.56%

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Novartis?

The following sell-side analysts have issued stock ratings on Novartis in the last twelve months: Barclays PLC, Berenberg Bank, BNP Paribas, Bryan, Garnier & Co, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Exane BNP Paribas, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Redburn Partners, Societe Generale, Stifel Nicolaus, StockNews.com, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for NVS.

What is the current price target for Novartis?

0 Wall Street analysts have set twelve-month price targets for Novartis in the last year. Their average twelve-month price target is $88.13, suggesting a possible upside of 5.2%.
View the latest price targets for NVS.

What is the current consensus analyst rating for Novartis?

Novartis currently has 2 sell ratings, 8 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVS, but not buy more shares or sell existing shares.
View the latest ratings for NVS.

How do I contact Novartis' investor relations team?

Novartis' physical mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company's listed phone number is (161) 324-1111 and its investor relations email address is [email protected] The official website for Novartis is www.novartis.com. Learn More about contacing Novartis investor relations.